Actionable early cardiovascular risk biomarker panel
This panel is intentionally small. That's what makes it useful.
A focused cardiovascular lab panel for people who care about clean signal, repeatable tracking, and results they can actually act on.
Most testing services optimize for coverage and automation—not for repeatability or interpretation. The result is more numbers, more variability, and less confidence in whether changes mean anything at all.
If you've ever wondered whether a result reflects real health change—or just noise—you're not alone.
What this panel measures:
ApoB — Atherogenic particle burden
ApoB reflects how many cholesterol-carrying particles are circulating in your blood. More particles mean more chances for cholesterol to enter artery walls over time.
Lp(a) — Inherited risk amplifier
Lp(a) is a cholesterol particle you’re mostly born with. It doesn’t change much, but higher levels can increase risk and mean other markers need tighter control.
hs-CRP — Vascular inflammation
hs-CRP shows whether there is low-grade inflammation affecting your blood vessels. Persistent inflammation can make arteries more vulnerable to damage over time.
HbA1c — Cumulative glucose exposure
HbA1c reflects your average blood sugar levels over the past few months. Higher values mean your blood vessels are exposed to more glucose than they should be.
Triglycerides — Metabolic / remnant lipid stress
Triglycerides show how your body handles sugars, fats, and alcohol. Elevated levels often mean excess fuel is circulating and stressing the system.
HDL-C — Metabolic health context
HDL helps transport cholesterol away from tissues. Lower levels often signal reduced metabolic fitness or underlying insulin resistance.
Homocysteine — Endothelial toxicity
Homocysteine is a byproduct of protein metabolism. When levels are high, it can irritate the lining of blood vessels and increase stress on the cardiovascular system.
If a number can't guide a decision, it doesn't belong on the panel.
We include only cardiovascular markers with strong clinical relevance, stable measurement, and a clear direction of change.
Designed to answer one question: "Is my cardiovascular risk actually improving?"
Not to generate alerts, dashboards, or false precision—just a reliable way to track meaningful change over time.
Cardiovascular risk is driven by a small number of well-studied pathways. Testing more markers doesn't necessarily improve insight—especially if results are unstable or hard to interpret.
This panel reflects clinical judgment about what holds up over time and what's worth paying attention to.
No promises of optimization. Just careful measurement.
No subscriptions. No dashboards. No upsells.
This is for you if:
This is an early, self-pay offering. Join the waitlist now and receive free complementary genetic testing for inherited genetic markers of cardiovascular disease.